CliffBio
small molecule

TANDEARIL

OXYPHENBUTAZONE

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameTANDEARIL
Active ingredientOXYPHENBUTAZONE
Strength100MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 1982
Marketing statusDISCN

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.